enrasentan
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Endothelin receptor ET-AANTAGONIST
EDNRA antagonist
- Endothelin receptor ET-BANTAGONIST
EDNRB antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCOc1ccc2c(c1)[C@@H](c1ccc(OC)cc1OCCO)[C@H](C(=O)O)[C@H]2c1ccc2c(c1)OCO2- Mol. weight
- 506.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL431651 ↗
Also known as
- (1s,2r,3s)-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-1-(3,4- (methylenedioxy)phenyl)-5-propoxy-2-indancarboxylic acid
- 3-(2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indan-2-carboxylic acid
- enrasentan
- enrasentan
- enrasentan
- sb 217242
- sb-217242
- sb-217242
- sb-217242